Study design: Experimental laboratory study.
Objectives: To measure the transmission of dexamethasone sodium phosphate (DEX-P) using iontophoresis as a function of skinfold tissue thickness and time elapsed between treatment and tissue extraction.
Background: Iontophoresis is a modality used in physical therapy with the intent to drive medications through the skin to underlying tissues using a direct electrical current. DEX-P is the most commonly used medication with iontophoresis and is used to treat a variety of connective tissue conditions.
Methods and measures: Sixteen adults undergoing anterior cruciate ligament reconstructive surgery using the semitendinosis/gracilis autograft received a 40-mA-min dose of iontophoresis with 0.4% DEX-P superficial to a slip of the distal semitendinosis tendon prior to surgery. The tendon slip was extracted within 4 hours. Time between treatment and tissue extraction and skinfold thickness were measured. Analysis was performed on the slip of the semitendinosis using high-performance liquid chromatography mass spectrum.
Results: Of the 16 subjects (10 female, 6 male; mean age, 33 years), 7 had measurable amounts of DEX-P in the tendon slip (4 female, 3 male; mean age, 34 years). The average concentration in the 16 subjects was 2.9 ng/g of tendon tissue. There was no correlation between DEX-P absorbed and skinfold thickness (r = -0.08, P = .79) or time elapsed (r = 0.25, P = .38). In a subset of the 7 individuals that showed measurable levels of DEX-P absorbed, the average concentration of DEX-P was 6.6 ng/g of tendon tissue, and there was a relationship between DEX-P concentrations and time elapsed that did not reach statistical significance (r = 0.71, P = .11).
Conclusions: Iontophoresis appears to facilitate the transmission of dexamethasone to connective tissues in humans with skinfold thickness up to at least 30 mm. The absorption of the dexamethasone seemed to continue to occur for up to 4 hours after delivery. It is not clear why DEX-P was measured in only 7 of the 16 subjects.
Level of evidence: Therapy, level 5.